Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Boceprevir

FDA-approved product (capsule, oral), marketed as Victrelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Boceprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Boceprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Boceprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Boceprevir and Ucalm (St John&Apos;s Wort)

    NCT01663922 · start 2012-08

    Registered record
    Registry ID
    NCT01663922
    Conditions
    Hepatitis C
    Interventions
    Boceprevir; St John's Wort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-08
    Completion
    2012-12
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionBoceprevir; St John's Wort
    PhasePhase 1
    Registry statusCompleted

  • Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

    NCT01597895 · start 2012-07

    Registered record
    Registry ID
    NCT01597895
    Conditions
    Healthy
    Interventions
    Maraviroc; Maraviroc + Boceprevir; Maraviroc + Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-08
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc; Maraviroc + Boceprevir; Maraviroc + Telaprevir
    PhasePhase 1
    Registry statusCompleted

  • The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

    NCT01627717 · start 2012-06

    Registered record
    Registry ID
    NCT01627717
    Conditions
    Healthy
    Interventions
    Maraviroc (5 days); Maraviroc and boceprevir (14 days)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2014-02
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc (5 days); Maraviroc and boceprevir (14 days)
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

    NCT01544920 · start 2012-05-30

    Registered record
    Registry ID
    NCT01544920
    Conditions
    Hepatitis C, Chronic
    Interventions
    peg-Interferon alfa-2a; Ribavirin; Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05-30
    Completion
    2015-05-19
    Enrolment
    737

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    Interventionpeg-Interferon alfa-2a; Ribavirin; Boceprevir
    PhasePhase 3
    Registry statusCompleted

  • Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)

    NCT01544582 · start 2012-05

    Registered record
    Registry ID
    NCT01544582
    Conditions
    Hepatitis C Chronic
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-05
    Completion
    2015-07
    Enrolment
    713

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Chronic
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers

    NCT01549496 · start 2012-05

    Registered record
    Registry ID
    NCT01549496
    Conditions
    Hepatitis C; Hypertension
    Interventions
    Amlodipine; Diltiazem
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2012-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Hypertension
    InterventionAmlodipine; Diltiazem
    PhasePhase 1
    Registry statusWithdrawn

  • Effect of Boceprevir on HCV-specific T Cell Responses

    NCT01403181 · start 2012-04

    Registered record
    Registry ID
    NCT01403181
    Conditions
    Chronic Hepatitis C
    Interventions
    Boceprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-04
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionBoceprevir
    PhaseNot recorded
    Registry statusCompleted

  • Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

    NCT01482767 · start 2012-04

    Registered record
    Registry ID
    NCT01482767
    Conditions
    HIV Infections; Hepatitis C
    Interventions
    Pegylated-Interferon Alfa 2b (PEG-IFN); Ribavirin (RBV); Boceprevir (BOC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2015-04
    Enrolment
    262

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hepatitis C
    InterventionPegylated-Interferon Alfa 2b (PEG-IFN); Ribavirin (RBV); Boceprevir (BOC)
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

    NCT01563328 · start 2012-03-01

    Registered record
    Registry ID
    NCT01563328
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    DTG; BCV; TVR
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-03-01
    Completion
    2012-05-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionDTG; BCV; TVR
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

    NCT01425190 · start 2012-01-04

    Registered record
    Registry ID
    NCT01425190
    Conditions
    Hepatitis C, Chronic
    Interventions
    Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-01-04
    Completion
    2013-03-20
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionBoceprevir
    PhasePhase 1
    Registry statusTerminated

  • Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients

    NCT02057003 · start 2012-01

    Registered record
    Registry ID
    NCT02057003
    Conditions
    Hepatitis C, Chronic; Human Immunodeficiency Virus
    Interventions
    DAA against HCV
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2012-01
    Completion
    2020-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Human Immunodeficiency Virus
    InterventionDAA against HCV
    PhaseNot recorded
    Registry statusUnknown

  • Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

    NCT01405027 · start 2011-12

    Registered record
    Registry ID
    NCT01405027
    Conditions
    Chronic Hepatitis C; Genotype 1
    Interventions
    Educational Intervention; Patient education and management skills training
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-07
    Enrolment
    197

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Genotype 1
    InterventionEducational Intervention; Patient education and management skills training
    PhasePhase 4
    Registry statusCompleted

  • Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

    NCT01446250 · start 2011-12

    Registered record
    Registry ID
    NCT01446250
    Conditions
    Hepatitis C
    Interventions
    Alisporivir; Boceprevir; Peginterferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2013-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionAlisporivir; Boceprevir; Peginterferon alfa-2a; Ribavirin
    PhasePhase 3
    Registry statusTerminated

  • Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.

    NCT01949077 · start 2011-12

    Registered record
    Registry ID
    NCT01949077
    Conditions
    Hepatitis C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2011-12
    Completion
    2016-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)

    NCT01457937 · start 2011-11

    Registered record
    Registry ID
    NCT01457937
    Conditions
    Chronic Hepatitis C; Menopause
    Interventions
    Pegylated Interferon, Ribavirin, Boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-11
    Completion
    2014-06
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Menopause
    InterventionPegylated Interferon, Ribavirin, Boceprevir
    PhasePhase 3
    Registry statusUnknown